OrbiMed Files to Sell $11.5M of Enliven Therapeutics Stock
ELVN has more than doubled off its 52-week low of $14.785 on elevated volume (2.1× avg).
Summary
A major institutional shareholder, OrbiMed, has filed to sell $11.5 million in Enliven Therapeutics stock, following recent positive drug data and a large public offering.
Key Events · Ownership and Investor Activity · ELVN
-
Intent to Sell Shares
OrbiMed Private Investments VII, LP, a significant shareholder, filed a Form 144 indicating its intent to sell 272,322 shares of Enliven Therapeutics common stock.
-
Significant Transaction Value
The proposed sale has an approximate market value of $11,535,559.92.
-
Follows Recent Capital Raise
This filing comes shortly after Enliven Therapeutics completed an upsized public offering, raising approximately $400 million on June 12, 2026.
-
Follows Positive Clinical Data
The intent to sell also follows the company's announcement of strong Phase 1 data for its lead CML drug ELVN-001 on June 11, 2026.
Analysis · ELVN · Life Sciences
OrbiMed Private Investments VII, LP, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell approximately $11.5 million worth of Enliven Therapeutics common stock. This filing follows closely on the heels of the company's announcement of positive Phase 1 clinical data for its lead drug candidate and a substantial $400 million public offering. While the sale is from a financial investor rather than an executive, the magnitude suggests profit-taking or portfolio rebalancing after recent positive developments and a dilutive capital raise.
At the time of this filing, ELVN was trading at $42.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $14.79 to $48.53. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.